PD-011 Efficacy, Safety and Timing of Dose Adjustment of Subcutaneous Ustekinumab Maintenance in Mod...
PD-011 Efficacy, Safety and Timing of Dose Adjustment of Subcutaneous Ustekinumab Maintenance in Moderate –Severe Crohn's Disease Patients in IM-UNITI
About this item
Full title
Author / Creator
Publisher
Oxford, UK: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
Oxford, UK: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Ustekinumab (UST) has been shown to induce and maintain clinical response and remission in moderate to severe Crohn's disease (CD) in 2 induction (UNITI-1 and 2) and 1 maintenance (IM-UNITI) randomized, placebo controlled Phase 3 trials. The efficacy of UST after dose adjustment following loss of response (LOR) was also examined in the randomized p...
Alternative Titles
Full title
PD-011 Efficacy, Safety and Timing of Dose Adjustment of Subcutaneous Ustekinumab Maintenance in Moderate –Severe Crohn's Disease Patients in IM-UNITI
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3169868579
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3169868579
Other Identifiers
ISSN
1078-0998
E-ISSN
1536-4844
DOI
10.1097/01.MIB.0000512535.31738.6a
